These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
412 related articles for article (PubMed ID: 9441282)
21. Staging in childhood lymphoma: differences between FDG-PET and CT. Hermann S; Wormanns D; Pixberg M; Hunold A; Heindel W; Jürgens H; Schober O; Franzius C Nuklearmedizin; 2005 Feb; 44(1):1-7. PubMed ID: 15711722 [TBL] [Abstract][Full Text] [Related]
22. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454 [TBL] [Abstract][Full Text] [Related]
23. [Current status of nuclear medicine. Clinical application of FDG-PET for cancer diagnosis. Malignant lymphoma]. Higuchi T Nihon Igaku Hoshasen Gakkai Zasshi; 2002 May; 62(6):278-83. PubMed ID: 12073634 [TBL] [Abstract][Full Text] [Related]
24. [Clinical value of FDG PET for therapy monitoring of malignant lymphoma--results of a retrospective study in 72 patients]. Cremerius U; Fabry U; Kröll U; Zimny M; Neuerburg J; Osieka R; Büll U Nuklearmedizin; 1999; 38(1):24-30. PubMed ID: 9987778 [TBL] [Abstract][Full Text] [Related]
25. FDG-PET in 10 children with non-Hodgkin's lymphoma: initial experience in staging and follow-up. Amthauer H; Furth C; Denecke T; Hundsdoerfer P; Voelker T; Seeger K; Stöver B; Henze G Klin Padiatr; 2005; 217(6):327-33. PubMed ID: 16307418 [TBL] [Abstract][Full Text] [Related]
26. Extranodal malignant lymphoma: detection with FDG PET versus CT. Moog F; Bangerter M; Diederichs CG; Guhlmann A; Merkle E; Frickhofen N; Reske SN Radiology; 1998 Feb; 206(2):475-81. PubMed ID: 9457202 [TBL] [Abstract][Full Text] [Related]
27. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Cremerius U; Fabry U; Neuerburg J; Zimny M; Osieka R; Buell U Nucl Med Commun; 1998 Nov; 19(11):1055-63. PubMed ID: 9861622 [TBL] [Abstract][Full Text] [Related]
28. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Blum RH; Seymour JF; Wirth A; MacManus M; Hicks RJ Clin Lymphoma; 2003 Jun; 4(1):43-9. PubMed ID: 12837154 [TBL] [Abstract][Full Text] [Related]
29. (18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging. Lopci E; Burnelli R; Ambrosini V; Nanni C; Castellucci P; Biassoni L; Rubello D; Fanti S Cancer Biother Radiopharm; 2008 Dec; 23(6):681-90. PubMed ID: 19111053 [TBL] [Abstract][Full Text] [Related]
30. Imaging of malignant lymphomas with F-18 FDG coincidence detection positron emission tomography. Hwang K; Park CH; Kim HC; Kim H; Yoon S; Pai M; Kim S Clin Nucl Med; 2000 Oct; 25(10):789-95. PubMed ID: 11043718 [TBL] [Abstract][Full Text] [Related]
31. The impact of FDG positron emission tomography imaging on the management of lymphomas. Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743 [TBL] [Abstract][Full Text] [Related]
32. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma. Ulaner GA; Lilienstein J; Gönen M; Maragulia J; Moskowitz CH; Zelenetz AD J Clin Oncol; 2014 Jan; 32(1):51-6. PubMed ID: 24248697 [TBL] [Abstract][Full Text] [Related]
33. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Stumpe KD; Urbinelli M; Steinert HC; Glanzmann C; Buck A; von Schulthess GK Eur J Nucl Med; 1998 Jul; 25(7):721-8. PubMed ID: 9662594 [TBL] [Abstract][Full Text] [Related]
34. 18F-FDG PET is superior to 67Ga SPECT in the staging of non-Hodgkin's lymphoma. Yamamoto F; Tsukamoto E; Nakada K; Takei T; Zhao S; Asaka M; Tamaki N Ann Nucl Med; 2004 Sep; 18(6):519-26. PubMed ID: 15515753 [TBL] [Abstract][Full Text] [Related]
35. (18)F-FDG PET and conventional imaging for assessment of Hodgkin's disease and non Hodgkin's lymphoma. An analysis of 193 patient studies. Bucerius J; Herkel C; Joe AY; Altehoefer C; Finke J; Moser E; Reinhardt MJ Nuklearmedizin; 2006; 45(3):105-10; quiz N25-6. PubMed ID: 16710505 [TBL] [Abstract][Full Text] [Related]
36. 18F-FDG-PET/CT in the surveillance of patients with lymphoma: detection of asymptomatic recurrences. García Vicente AM; Bellón Guardia M; Soriano Castrejón A; Calle Primo C; Cordero García JM; Palomar Muñoz A; Pilkington Woll JP; Talavera Rubio MP; Hernández Ruiz B Rev Esp Med Nucl Imagen Mol; 2012; 31(1):22-7. PubMed ID: 21742419 [TBL] [Abstract][Full Text] [Related]
37. [Positron-emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment]. Mainolfi C; Maurea S; Varrella P; Alaia C; Imparato C; Alfano B; Abate G; Bazzicalupo L Radiol Med; 1998; 95(1-2):98-104. PubMed ID: 9636735 [TBL] [Abstract][Full Text] [Related]
38. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas. Specht L Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566 [TBL] [Abstract][Full Text] [Related]
39. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Jerusalem G; Warland V; Najjar F; Paulus P; Fassotte MF; Fillet G; Rigo P Nucl Med Commun; 1999 Jan; 20(1):13-20. PubMed ID: 9949408 [TBL] [Abstract][Full Text] [Related]
40. Beyond the lymph nodes: FDG-PET/CT in primary extranodal lymphoma. Sin KM; Ho SK; Wong BY; Gill H; Khong PL; Lee EY Clin Imaging; 2017; 42():25-33. PubMed ID: 27875758 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]